PURPOSE: We examined the biodistribution and pharmacokinetics of (111)In-labeled rGel/BLyS, a gelonin toxin (rGel)-B lymphocyte stimulator (BLyS) fusion protein. MATERIALS AND METHODS: rGel/BLyS was labeled with In-111 through DTPA with a labeling efficiency >95%. Biodistribution/imaging studies were obtained in severe-combined immunodeficiency mice bearing diffuse large B cell lymphoma OCI-Ly10. Pharmacokinetic studies were performed in BALB/c mice. RESULTS: In vitro, DTPA-conjugated rGel/BLyS displayed selective cytotoxicity against OCI-Ly10 cells and mantle cell lymphoma JeKo cells. In vivo, rGel/BLyS exhibited a tri-exponential disposition with a rapid initial mean distribution followed by an extensive mean distribution and a long terminal elimination phase. At 48 h after injection, uptake of the radiotracer in tumors was 1.25 %ID/g, with a tumor-to-blood ratio of 13. Tumors were clearly visualized at 24-72 h post-injection. Micro-SPECT-CT images and ex vivo analyses confirmed the accumulation of rGel/BLyS in OCI-Ly10 tumors. CONCLUSIONS: (111)In-DTPA-rGel/BLyS are distributed to B cell tumors and induce apoptosis in tumors. Preclinical antitumor studies using rGel/BLyS should use a twice-per-week treatment schedule.
PURPOSE: We examined the biodistribution and pharmacokinetics of (111)In-labeled rGel/BLyS, a gelonin toxin (rGel)-B lymphocyte stimulator (BLyS) fusion protein. MATERIALS AND METHODS: rGel/BLyS was labeled with In-111 through DTPA with a labeling efficiency >95%. Biodistribution/imaging studies were obtained in severe-combined immunodeficiencymice bearing diffuse large B cell lymphoma OCI-Ly10. Pharmacokinetic studies were performed in BALB/c mice. RESULTS: In vitro, DTPA-conjugated rGel/BLyS displayed selective cytotoxicity against OCI-Ly10 cells and mantle cell lymphoma JeKo cells. In vivo, rGel/BLyS exhibited a tri-exponential disposition with a rapid initial mean distribution followed by an extensive mean distribution and a long terminal elimination phase. At 48 h after injection, uptake of the radiotracer in tumors was 1.25 %ID/g, with a tumor-to-blood ratio of 13. Tumors were clearly visualized at 24-72 h post-injection. Micro-SPECT-CT images and ex vivo analyses confirmed the accumulation of rGel/BLyS in OCI-Ly10 tumors. CONCLUSIONS: (111)In-DTPA-rGel/BLyS are distributed to B cell tumors and induce apoptosis in tumors. Preclinical antitumor studies using rGel/BLyS should use a twice-per-week treatment schedule.
Authors: Ramadevi Nimmanapalli; Mi-Ae Lyu; Min Du; Michael J Keating; Michael G Rosenblum; Varsha Gandhi Journal: Blood Date: 2006-11-21 Impact factor: 22.113
Authors: Todd A Riccobene; Renée C Miceli; Clint Lincoln; Yvonne Knight; Joseph Meadows; Michael G Stabin; Cynthia Sung Journal: J Nucl Med Date: 2003-03 Impact factor: 10.057
Authors: Mi-Ae Lyu; Lawrence H Cheung; Walter N Hittelman; John W Marks; Ricardo C T Aguiar; Michael G Rosenblum Journal: Mol Cancer Ther Date: 2007-01-31 Impact factor: 6.261
Authors: P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp Journal: J Exp Med Date: 1999-06-07 Impact factor: 14.307
Authors: Andrew J Buckler; Tiffany Ting Liu; Erica Savig; Baris E Suzek; M Ouellette; J Danagoulian; G Wernsing; Daniel L Rubin; David Paik Journal: J Digit Imaging Date: 2013-08 Impact factor: 4.056
Authors: Andrew J Buckler; David Paik; Matt Ouellette; Jovanna Danagoulian; Gary Wernsing; Baris E Suzek Journal: J Digit Imaging Date: 2013-08 Impact factor: 4.056
Authors: Jiehua Zhou; Katrin Tiemann; Pritsana Chomchan; Jessica Alluin; Piotr Swiderski; John Burnett; Xizhe Zhang; Stephen Forman; Robert Chen; John Rossi Journal: Nucleic Acids Res Date: 2013-03-06 Impact factor: 16.971